Drug discovery

New drug application
#ADME / Tox #Drug discovery #Regulatory #Whitepaper

Whitepaper: Secure your place in the IND race

A new exclusive whitepaper is now available from Lonza entitled ‘Secure your place in the IND race with a rapid tox approach‘. Early tox material can offer valuable clarity as programmes progress toward IND. Lonza’s latest whitepaper introduces a new offering that helps drug developers shorten timelines and generate… Read More

#News

Theranostic radiopharmaceuticals
#Drug discovery #Radiopharmaceuticals

New protein drugs could pave way for faster drug development 

A new class of protein drugs have shown amenability to multiple isotopes, paving the way for faster radiopharmaceutical drug development.  Biotechnology company Molecular Partners announced preclinical data showing its Radio-DARPins are suitable to different isotopes, each specific for a different tumour target.   DARPin (Designed Ankyrin Repeat Protein)… Read More

#News

CAR-T in multiple myeloma
#Biotech #Cancer research #CAR-T #Drug discovery #Oncology

The next generation of CAR-T cell therapies

Drug Discovery World Editor Reece Armstrong speaks to Dr Jan Davidson-Moncada, Chief Medical Officer at Imviva Biotech about the development of CAR-T cell therapies and the company’s activities in this space.   RA: What are the biggest challenges when developing CAR-T cell therapies?   JDM: CAR-T therapies face several formidable barriers. Autologous approaches made from a patient’s own T-cells are… Read More

#Exclusive Content

#Biotech #Drug discovery #Financing #Oncology

Laigo Bio raises $17m to advance oncology pipeline  

Biotech company Laigo Bio has completed the second close of its seed financing round with an additional $5.5 million bringing the total investment to $17 million.   Laigo will use the seed financing to accelerate the development of its Surface Removal Targeting Chimeras (SureTACs) oncology programmes towards the clinic. It will also advance three… Read More

#Business & Investment #News

The European Medicines Agency in Amsterdam
#Drug discovery #European Medicines Agency #Regulatory

EMA launches tools to accelerate development of medicines

The European Medicines Agency (EMA) has launched three major new features of PRIME, the Agency’s scheme to enhance support for the development of medicines targeting an unmet medical need.   After the completion of a two-year pilot, the EMA has integrated these additional tools to support continued scientific dialogue, aiming to… Read More

#News #Regulatory

Obesity concept
#Drug development #Drug discovery

Read the latest issue of DDW

The new issue of DDW is now on its way to subscribers and available to read online. The Spring issue explores the next phase of obesity medications and asks how US tariffs are impacting global pharma. It also looks at how India is… Read More

#Editor's Choice #News

#Drug discovery #Orphan drugs #Rare diseases

Rare disease drugs to generate $400bn by 2032, report reveals 

Rare disease therapies could generate over $400 billion in global sales by 2032, a new report reveals.   Evaluate’s ‘2026 Orphan Drug Report’ predicts the sales of orphan drugs will continue to rise steadily, despite policy changes and pricing turmoil. According to the forecast, orphan drugs will account for over 21% of… Read More

#Business & Investment #News

#Biomarkers #Drug discovery #Epigenetics #Idiopathic pulmonary fibrosis #Medicines Discovery Catapult

How spatial epigenetics is unlocking new frontiers in drug discovery

Michael Eyres, Lead Scientist at the Medicines Discovery Catapult (MDC), explores how spatial epigenetics can accelerate biomarker drug discovery.   Epigenetics, once seen as a cryptic mix of marks on our DNA, is now central to our understanding of gene regulation in health and disease. Until recently, we studied epigenetics only in bulk tissues or single cells. But with emerging… Read More

#Exclusive Content

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Biotherapeutics #Drug discovery #eBook

eBook: A smarter path to ADC quality – fractionate, analyse, decide

A new eBook is now available to download from Bio-Techne entitled ‘Advances in the analysis of next-generation biotherapeutics’. Discover how to accelerate ADC development with clearer, faster characterisation of charge heterogeneity and size/purity. This eBook explains when to apply advanced icIEF and CE-SDS methods for ADCs and other novel biotherapeutics… Read More

#News

#Antibody drug conjugate (ADC) #Biotherapeutics #Drug discovery #eBook

Advances in the analysis of next-generation biotherapeutics

Discover how to accelerate ADC development with clearer, faster characterisation of charge heterogeneity and size/purity. This eBook explains when to apply advanced icIEF and CE-SDS methods for ADCs and other novel biotherapeutics to accelerate development timelines. Learn: icIEF vs IEX for ADC charge profiles Protecting unstable ADCs with on-board mixing… Read More

#eBooks #Resources

BioNTech HQ
#BioNTech #Drug discovery #mRNA

BioNTech co-founders launch new mRNA company

An independent company is to be established and led by BioNTech co-founders Professor Ugur Sahin and Professor Özlem Türeci to “advance next-generation mRNA innovations”.   BioNTech has announced plans to contribute related rights and mRNA technologies to the new company to support the prioritised development of mRNA innovations with “disruptive potential”. … Read More

#Business & Investment #News

#Drug discovery #Immunology #Nobel Prize #Osteoporosis #Systems biology

Meet the researcher: Mary Brunkow, Nobel winner 

Mary Brunkow PhD is Senior Program Manager at the Institute for Systems Biology in Seattle in the US. She was one of three co-winners of the 2025 Nobel Prize in Physiology or Medicine for the discovery of regulatory T cells (Tregs). She shares her career highlights and some word of wisdom with Diana Turner.  DT: What do you do… Read More

#Exclusive Content #Opinion

#Clinical trial #Drug discovery #ischaemic stroke #Proteins

How DiaMedica aims to reshape treatments for ischemic diseases

DDW Editor Reece Armstrong speaks to Rick Pauls, CEO of DiaMedica, about the company’s efforts in ischemic diseases and the challenges of drug discovery in this field.   RA: How did DiaMedica decide to explore the therapy area of ischemia?   RP: Ischemic diseases driven by restricted blood flow and endothelial dysfunction, such as preeclampsia (PE), fetal growth restriction (FGR), and… Read More

#Exclusive Content

#Autoimmune disease #Drug discovery #Infectious diseases

Asahi Kasei Pharma strengthens drug discovery pipeline 

Asahi Kasei Pharma has announced a global license agreement with Alchemedicine to strengthen its drug discovery pipeline.  The agreement means Asahi Kasei Pharma can research, develop, manufacture, and commercialise Alchemedicine’s novel lead compounds, which are currently at the preclinical stage.  The compounds were identified using Alchemedicine’s drug discovery platform, HiSAP1 and are expected to have therapeutic potential for multiple… Read More

#Business & Investment #News